 COPENHAGEN, Denmark, July 08, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX, a clinical-stage biotech company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today results from both its Phase 12a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 12a trial of cancer immunotherapy EVX-02 in adjuvant melanoma. 